Brief: SynAct Pharma Q3 Sales SEK 0
30/10/2024 06:30
Oct 30 (Reuters) - SynAct Pharma Q3 cash flow from operating activities SEK -24.076 million. * Q3 adjusted EPS SEK -0.5 * Q3 operating expenses SEK 24.309 million * Q3 net income SEK -20.489 million
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development